ABDX vs. AGL, YGEN, PRM, GDR, VRCI, GENI, DMTR, LLAI, LLA, and IDHC
Should you be buying Abingdon Health stock or one of its competitors? The main competitors of Abingdon Health include ANGLE (AGL), Yourgene Health (YGEN), Proteome Sciences (PRM), genedrive (GDR), Verici Dx (VRCI), GENinCode (GENI), Deepmatter Group (DMTR), LungLife AI (LLAI), LLA.L,0P0001T9GN,0 (LLA), and Integrated Diagnostics (IDHC). These companies are all part of the "diagnostics & research" industry.
Abingdon Health vs.
ANGLE (LON:AGL) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation.
In the previous week, ANGLE's average media sentiment score of 0.00 equaled Abingdon Health'saverage media sentiment score.
Abingdon Health has a net margin of -20.72% compared to ANGLE's net margin of -890.91%. Abingdon Health's return on equity of -62.56% beat ANGLE's return on equity.
ANGLE has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Abingdon Health has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500.
ANGLE received 183 more outperform votes than Abingdon Health when rated by MarketBeat users.
Abingdon Health has higher revenue and earnings than ANGLE. Abingdon Health is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.
18.8% of ANGLE shares are held by institutional investors. Comparatively, 33.5% of Abingdon Health shares are held by institutional investors. 16.2% of ANGLE shares are held by insiders. Comparatively, 48.9% of Abingdon Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
ANGLE presently has a consensus price target of GBX 40, indicating a potential upside of 290.24%. Given ANGLE's stronger consensus rating and higher possible upside, research analysts clearly believe ANGLE is more favorable than Abingdon Health.
Summary
Abingdon Health beats ANGLE on 8 of the 15 factors compared between the two stocks.
Get Abingdon Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABDX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abingdon Health Competitors List
Related Companies and Tools
This page (LON:ABDX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ABDX Stock Free ABDX Stock Alerts